Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 5/2019

12.02.2019 | Gynecologic Oncology

Identification of 3q oncogene SEC62 as a marker for distant metastasis and poor clinical outcome in invasive ductal breast cancer

verfasst von: Ferenc Zoltan Takacs, Julia Caroline Radosa, Maximilian Linxweiler, Mariz Kasoha, Rainer M. Bohle, Florian Bochen, Clara Unger, Erich-Franz Solomayer, Bernard Schick, Ingolf Juhasz-Böss

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In previous studies, we have shown that SEC62 has an essential function in cell migration, epithelial-to-mesenchymal transition, and endoplasmic reticulum stress tolerance of cancer cells. SEC62 expression correlated with distant and lymph node metastasis and poor outcome in different cancer entities. In this initial study, we investigated SEC62 expression and its possible role as a prognostic and predictive biomarker in breast cancer (BC).

Methods

Formalin-fixed, paraffin-embedded tissue samples of 53 BC patients were analyzed by immunohistochemistry. The immunoreactive score (IRS) according to Remmele and Stegner was evaluated and correlated with clinico-pathological findings and overall survival (OS).

Results

We found increased SEC62 protein levels in tumor tissue compared to tumor-free tissue samples from the same patients. Tumors with high SEC62 expression (IRS > 8), or containing isolated cells with high SEC62 staining intensity, independent of the IRS, had more frequently distant metastases (48.4% vs. 18.2%; p = 0.024 and 47.4 vs. 6.7%; p = 0.005, respectively). Overall survival was significantly worse in BC patients with high SEC62 expression (SEC62 IRS > 8) (54.8% vs. 81.8%; p = 0.011) and in cases with isolated high-intensity SEC62 staining cells independently of SEC62 IRS (55.3% vs 93.3%; p = 0.024).

Conclusions

We are the first to describe the SEC62 expression and its correlation to clinicopathological parameters in mammary carcinoma. Our results suggest that SEC62 expression may serve as a prognostic marker for patients with invasive ductal breast cancer.
Literatur
1.
Zurück zum Zitat Torre L, Islami F, Siegel R, Ward E, Jemal A (2017) Global cancer in women: burden and trends. Cancer Epidemiol Biomark 26:444CrossRef Torre L, Islami F, Siegel R, Ward E, Jemal A (2017) Global cancer in women: burden and trends. Cancer Epidemiol Biomark 26:444CrossRef
2.
3.
Zurück zum Zitat Horwitz K, McGuire W (1975) Specific progesterone receptors in human breast cancer. Steroids 25:497–505CrossRefPubMed Horwitz K, McGuire W (1975) Specific progesterone receptors in human breast cancer. Steroids 25:497–505CrossRefPubMed
4.
Zurück zum Zitat Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182CrossRef Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182CrossRef
5.
Zurück zum Zitat Goldhirsch A, Winer EP, Coates A et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24:2206–2223CrossRefPubMedPubMedCentral Goldhirsch A, Winer EP, Coates A et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24:2206–2223CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Taneja P, Maglic D, Kai F, Zhu S, Kendig RD, Fry EA, Inoue K (2010) Classical and novel prognostic markers for breast cancer and their clinical significance. Clin Med Insights Oncol 4:15–34CrossRefPubMedPubMedCentral Taneja P, Maglic D, Kai F, Zhu S, Kendig RD, Fry EA, Inoue K (2010) Classical and novel prognostic markers for breast cancer and their clinical significance. Clin Med Insights Oncol 4:15–34CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Prat A, Cheang MCU, Martín M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TONCMP (2012) Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31:203–209CrossRefPubMedPubMedCentral Prat A, Cheang MCU, Martín M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TONCMP (2012) Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31:203–209CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Prat A, Parker J, Fan C, Cheang M, Miller L, Bergh J, Chia S, Bernard P, Nielsen T, Ellis M, Carey LA, Perou C (2012) Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol 23:2866–2873CrossRefPubMedPubMedCentral Prat A, Parker J, Fan C, Cheang M, Miller L, Bergh J, Chia S, Bernard P, Nielsen T, Ellis M, Carey LA, Perou C (2012) Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol 23:2866–2873CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Linxweiler M, Linxweiler J, Barth M, Benedix J, Jung V, Kim Y-J, Bohle RM, Zimmermann R, Greiner M (2012) Sec62 bridges the gap from 3q amplification to molecular cell biology in non-small cell lung cancer. Am J Pathol 180:473–483CrossRefPubMed Linxweiler M, Linxweiler J, Barth M, Benedix J, Jung V, Kim Y-J, Bohle RM, Zimmermann R, Greiner M (2012) Sec62 bridges the gap from 3q amplification to molecular cell biology in non-small cell lung cancer. Am J Pathol 180:473–483CrossRefPubMed
11.
Zurück zum Zitat Jung V, Kindich R, Kamradt J, Jung M, Müller M, Schulz WA, Engers R, Unteregger G, Stӧckle M, Zimmermann R, Wullich B (2006) Genomic and expression analysis of the 3q25-q26 amplification unit reveals TLOC1/SEC62 as a probable target gene in prostate cancer. Mol Cancer Res 4:169–176CrossRefPubMed Jung V, Kindich R, Kamradt J, Jung M, Müller M, Schulz WA, Engers R, Unteregger G, Stӧckle M, Zimmermann R, Wullich B (2006) Genomic and expression analysis of the 3q25-q26 amplification unit reveals TLOC1/SEC62 as a probable target gene in prostate cancer. Mol Cancer Res 4:169–176CrossRefPubMed
12.
Zurück zum Zitat Greiner M, Kreutzer B, Jung V, Grobholz R, Hasenfus A, Stöhr RF, Tornillo L, Dudek J, Stöckle M, Unteregger G, Kamradt J, Wullich B, Zimmermann R (2011) Silencing of the SEC62 gene inhibits migratory and invasive potential of various tumor cells. Int J Cancer 128:2284–2295. https://doi.org/10.1002/ijc.25580 CrossRefPubMed Greiner M, Kreutzer B, Jung V, Grobholz R, Hasenfus A, Stöhr RF, Tornillo L, Dudek J, Stöckle M, Unteregger G, Kamradt J, Wullich B, Zimmermann R (2011) Silencing of the SEC62 gene inhibits migratory and invasive potential of various tumor cells. Int J Cancer 128:2284–2295. https://​doi.​org/​10.​1002/​ijc.​25580 CrossRefPubMed
13.
Zurück zum Zitat Wemmert S, Lindner Y, Linxweiler J, Wagenpfeil S, Bohle R, Niewald M, Schick B (2016) Initial evidence for Sec62 as a prognostic marker in advanced head and neck squamous cell carcinoma. Oncol Lett 11:1661–1670CrossRefPubMedPubMedCentral Wemmert S, Lindner Y, Linxweiler J, Wagenpfeil S, Bohle R, Niewald M, Schick B (2016) Initial evidence for Sec62 as a prognostic marker in advanced head and neck squamous cell carcinoma. Oncol Lett 11:1661–1670CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Bochen F, Adisurya H, Wemmert S, Lerner C, Greiner M, Zimmermann R, Hasenfus A, Wagner M, Smola S, Pfuhl T, Bozzato A, Kadah BA, Schick B, Linxweiler M (2017) Effect of 3q oncogenes SEC62 and SOX2 on lymphatic metastasis and clinical outcome of head and neck squamous cell carcinomas. Oncotarget 8:4922CrossRefPubMed Bochen F, Adisurya H, Wemmert S, Lerner C, Greiner M, Zimmermann R, Hasenfus A, Wagner M, Smola S, Pfuhl T, Bozzato A, Kadah BA, Schick B, Linxweiler M (2017) Effect of 3q oncogenes SEC62 and SOX2 on lymphatic metastasis and clinical outcome of head and neck squamous cell carcinomas. Oncotarget 8:4922CrossRefPubMed
16.
Zurück zum Zitat Hagerstrand D, Tong A, Schumacher SE, Ilic N, Shen RR, Cheung HW, Vazquez F, Shrestha Y, Kim SY, Giacomelli AO, Rosenbluh Joseph, Schinzel AC, Spardy NA, Barbie DA, Mermel CH, Weir BA, Garraway LA, Tamayo P, Mesirov JP, Beroukhim R, Hahn WC (2013) Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov 3:1044–1057CrossRefPubMedPubMedCentral Hagerstrand D, Tong A, Schumacher SE, Ilic N, Shen RR, Cheung HW, Vazquez F, Shrestha Y, Kim SY, Giacomelli AO, Rosenbluh Joseph, Schinzel AC, Spardy NA, Barbie DA, Mermel CH, Weir BA, Garraway LA, Tamayo P, Mesirov JP, Beroukhim R, Hahn WC (2013) Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov 3:1044–1057CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750CrossRefPubMedPubMedCentral Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Remmele W (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140 Remmele W (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140
19.
Zurück zum Zitat Gospodarowicz MK, Brierley JD, Wittekind C, et al. (eds) (2017) TNM classification of malignant tumours. Wiley, Oxford Gospodarowicz MK, Brierley JD, Wittekind C, et al. (eds) (2017) TNM classification of malignant tumours. Wiley, Oxford
20.
Zurück zum Zitat Weng L, Du J, Zhou Q, Cheng B, Li J, Zhang D, Ling C (2012) Identification of cyclin B1 and Sec62 as biomarkers for recurrence in patients with HBV-related hepatocellular carcinoma after surgical resection. Mol Cancer 11:39CrossRefPubMedPubMedCentral Weng L, Du J, Zhou Q, Cheng B, Li J, Zhang D, Ling C (2012) Identification of cyclin B1 and Sec62 as biomarkers for recurrence in patients with HBV-related hepatocellular carcinoma after surgical resection. Mol Cancer 11:39CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Troester MA, Hoadley KA, Sørlie T, Herbert B-S, Børresen-Dale A-L, Lønning PE, Shay JW, Kaufmann WK, Perou CM (2004) Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 64:4218–4226CrossRefPubMed Troester MA, Hoadley KA, Sørlie T, Herbert B-S, Børresen-Dale A-L, Lønning PE, Shay JW, Kaufmann WK, Perou CM (2004) Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 64:4218–4226CrossRefPubMed
23.
Zurück zum Zitat Linxweiler M, Bochen F, Schick B, Wemmert S, Al Kadah B, Greiner M, Hasenfus A, Bohle R-M, Juhasz-Bӧss I, Solomayer E-F, Takacs ZF (2016) Identification of SEC62 as a potential marker for 3q amplification and cellular migration in dysplastic cervical lesions. BMC cancer 16:676CrossRefPubMedPubMedCentral Linxweiler M, Bochen F, Schick B, Wemmert S, Al Kadah B, Greiner M, Hasenfus A, Bohle R-M, Juhasz-Bӧss I, Solomayer E-F, Takacs ZF (2016) Identification of SEC62 as a potential marker for 3q amplification and cellular migration in dysplastic cervical lesions. BMC cancer 16:676CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Müller P, Bischoff J, Harich D, Schlimok G, Gert Riethmüller RE, Klein CA (2003) From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci 100:7737–7742CrossRefPubMed Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Müller P, Bischoff J, Harich D, Schlimok G, Gert Riethmüller RE, Klein CA (2003) From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci 100:7737–7742CrossRefPubMed
25.
Zurück zum Zitat Linxweiler M, Schorr S, Schäuble N, Jung M, Linxweiler J, Langer F, Schäfers H-J, Cavalié A, Zimmermann R, Greiner M (2013) Targeting cell migration and the endoplasmic reticulum stress response with calmodulin antagonists: a clinically tested small molecule phenocopy of SEC62 gene silencing in human tumor cells. BMC Cancer 13:574CrossRefPubMedPubMedCentral Linxweiler M, Schorr S, Schäuble N, Jung M, Linxweiler J, Langer F, Schäfers H-J, Cavalié A, Zimmermann R, Greiner M (2013) Targeting cell migration and the endoplasmic reticulum stress response with calmodulin antagonists: a clinically tested small molecule phenocopy of SEC62 gene silencing in human tumor cells. BMC Cancer 13:574CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Linxweiler M, Schick B, Zimmermann R (2017) Let’s talk about Secs: Sec61, Sec62 and Sec63 in signal transduction, oncology and personalized medicine. Signal Transduct Target Ther 2:17002CrossRefPubMedPubMedCentral Linxweiler M, Schick B, Zimmermann R (2017) Let’s talk about Secs: Sec61, Sec62 and Sec63 in signal transduction, oncology and personalized medicine. Signal Transduct Target Ther 2:17002CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Zacharski LR, Moritz TE, Haakenson CM, O’Donnell JF, Ballard HS, Johnson GJ, Ringenberg QS, Schilsky RL, Spaulding MB, Tornyos K (1990) Chronic calcium antagonist use in carcinoma of the lung and colon: a retrospective cohort observational study. Cancer Investig 8:451–458CrossRef Zacharski LR, Moritz TE, Haakenson CM, O’Donnell JF, Ballard HS, Johnson GJ, Ringenberg QS, Schilsky RL, Spaulding MB, Tornyos K (1990) Chronic calcium antagonist use in carcinoma of the lung and colon: a retrospective cohort observational study. Cancer Investig 8:451–458CrossRef
28.
Zurück zum Zitat Jackisch C, Hahm HA, Tombal B, McCloskey D, Butash K, Davidson NE, Denmeade SR (2000) Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells. Clin Cancer Res 6:2844–2850PubMed Jackisch C, Hahm HA, Tombal B, McCloskey D, Butash K, Davidson NE, Denmeade SR (2000) Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells. Clin Cancer Res 6:2844–2850PubMed
29.
Zurück zum Zitat Mahalingam D, Wilding G, Denmeade S, Sarantopoulas J, Cosgrove D, Cetnar J, Azad N, Bruce J, Kurman M, Allgood V, Carducci M (2016) Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours. Br J Cancer 114:986–994CrossRefPubMedPubMedCentral Mahalingam D, Wilding G, Denmeade S, Sarantopoulas J, Cosgrove D, Cetnar J, Azad N, Bruce J, Kurman M, Allgood V, Carducci M (2016) Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours. Br J Cancer 114:986–994CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, Isaacs JT (2012) Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med 4:14–22. https://doi.org/10.1126/scitranslmed.3003886 CrossRef Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, Isaacs JT (2012) Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med 4:14–22. https://​doi.​org/​10.​1126/​scitranslmed.​3003886 CrossRef
33.
Zurück zum Zitat Fumagalli F, Noack J, Bergmann TJ, Cebollero E, Pisoni GB, Fasana E, Fregno I, Galli C, Loi M, Soldà T, D’Antuono R, Raimondi A, Jung M, Melnyk A, Schorr S, Schreiber A, Simonelli L, Varani L, Wilson-Zbinden C, Zerbe O, Hofmann K, Peter M, Quadroni M, Zimmermann R, Molinari M (2016) Translocon component Sec62 acts in endoplasmic reticulum turnover during stress recovery. Nat Cell Biol 18:1173–1184CrossRefPubMed Fumagalli F, Noack J, Bergmann TJ, Cebollero E, Pisoni GB, Fasana E, Fregno I, Galli C, Loi M, Soldà T, D’Antuono R, Raimondi A, Jung M, Melnyk A, Schorr S, Schreiber A, Simonelli L, Varani L, Wilson-Zbinden C, Zerbe O, Hofmann K, Peter M, Quadroni M, Zimmermann R, Molinari M (2016) Translocon component Sec62 acts in endoplasmic reticulum turnover during stress recovery. Nat Cell Biol 18:1173–1184CrossRefPubMed
Metadaten
Titel
Identification of 3q oncogene SEC62 as a marker for distant metastasis and poor clinical outcome in invasive ductal breast cancer
verfasst von
Ferenc Zoltan Takacs
Julia Caroline Radosa
Maximilian Linxweiler
Mariz Kasoha
Rainer M. Bohle
Florian Bochen
Clara Unger
Erich-Franz Solomayer
Bernard Schick
Ingolf Juhasz-Böss
Publikationsdatum
12.02.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 5/2019
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-019-05081-4

Weitere Artikel der Ausgabe 5/2019

Archives of Gynecology and Obstetrics 5/2019 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.